{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Life-threatening adverse experience. An AE or suspected adverse reaction is considered', 'life-threatening if, in the view of either the Investigator or the Sponsor, its occurrence', 'places the subject at immediate risk of death. It does not include an AE or suspected', 'adverse reaction that, had it occurred in a more severe form, might have caused death.', 'Persistent or significant disability or incapacity.', 'Inpatient hospitalization or prolongation of an existing hospitalization.', 'Congenital anomaly or birth defect.', 'Other medically important event which, according to appropriate medical judgment, may', 'require medical or surgical intervention to prevent one of the outcomes listed above.', 'Surgical procedures or other therapeutic interventions themselves are not AEs, but the condition', 'for which the surgery/intervention is required is an AE and should be documented accordingly.', 'Elective surgeries that require hospitalization and treatment received at an emergency room or', 'similar facility will not be considered as SAEs unless one of the definitions of an SAE listed', 'above is met.', 'In addition, hospitalizations for planned procedures are not considered an AE unless they are', 'prolonged hospitalizations, and emergency room visits less than 24 hours in duration are not', 'considered hospitalizations.', '9.5.5.1.1.3 Non-Serious Adverse Event Definition', 'A non-serious AE includes any AE that is not described in the previous SAE category.', '9.5.5.1.1.4 Unexpected Adverse Event Definition', 'An AE or suspected adverse reaction is considered unexpected if it is not listed in the Reference', 'Safety Information section of the IB or is not listed with the specificity or severity that has been', 'observed. Unexpected, as used in this definition, also refers to AEs or suspected adverse', 'reactions that are mentioned in the Reference Safety Information as occurring with a class of', 'drugs or as anticipated from the pharmacological properties of the drug, but are not specifically', 'mentioned as occurring with the particular drug under investigation.', '9.5.5.1.1.5 Adverse Events of Special Interest', 'Based on previous clinical experience in TED, the following AESIs are identified for this study', '(See Section 7.1.3.4.5.5 for further information):', 'Infusion reactions (e.g., nausea, vomiting, facial flushing, warmth, dyspnea, dizziness,', 'hypertension, hypotension, pruritus)', 'Hyperglycemia', 'Muscle spasms', 'Diarrhea', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 83 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9.5.5.1.2 Documentation of Adverse Events', 'Adverse events that occur within 2 weeks prior to Day 1 and prior to dosing on Day 1 will be', 'considered baseline signs/symptoms. The TEAE reporting period begins with administration of', 'the first dose of study medication on Day 1 and continues until 3 weeks after the last dose of', 'study drug, and the Follow-Up AE reporting period begins 3 weeks after the last dose of study', 'drug through completion of the Follow-Up Period (Week 72 or PW). All baseline', 'signs/symptoms, TEAEs, and AEs during the Follow-Up Period must be recorded in the source', \"documents and on the subject's eCRF.\", 'If the Investigator observes an SAE after study completion that he/she believes was possibly', 'caused by the study medication, the Investigator will report this SAE using the procedures', 'described in Section 9.5.5.1.5.', 'Detailed information regarding all SAEs must also be recorded on the Serious Adverse Event', 'Reporting Form. Whenever possible, the Investigator should group together into a single term', 'the signs and symptoms that constitute a single diagnosis. For example, cough, rhinitis, and', 'sneezing might be grouped together as \"upper respiratory infection\" if the Investigator is', 'confident of the diagnosis.', '9.5.5.1.3 Intensity of Adverse Events', 'All clinical AEs encountered during the clinical study will be reported on the AE form of the', 'CRF. Intensity of AEs will be graded on a 5-point scale (mild, moderate, severe, life-threatening,', 'death) and reported in detail on the eCRF.', 'Intensity', 'Definition', 'Corresponding NCI Grade', 'Mild', 'discomfort noticed but no disruption of normal daily activity', '1', 'Moderate', 'discomfort sufficient to reduce or affect daily activity', '2', 'Severe', 'inability to work or perform normal daily activity', '3', 'Life-Threatening', 'represents an immediate threat to life', '4', 'Fatal', 'results in death', '5', '9.5.5.1.4 Relationship to Study Drug', 'The relationship of the study drug to each AE will be determined by the Investigator and the', 'Sponsor based on the following definitions:', 'No reasonable causal relationship (probably not related): There is no plausible temporal', 'relationship or there is another explanation that unequivocally provides a more plausible', 'explanation for the event.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 84 of 117']\n\n###\n\n", "completion": "END"}